This Combined Synopsis/Solicitation opportunity from Department Of Health And Human Services was posted on November 15, 2024. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Transcriptomics Sequencing and analysis in Liver Spheroids

Closed

75N95025Q00040Federal

Submission Closed11/22/2024, 08:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325414

New

Federal

Brand Name - Dectomax (Doramectin) 500mL Injectable Solution

Solicitation # 12639527Q0009

Solicitation 12639527Q0009 is a combined synopsis and request for quotation issued by the Department of Agriculture for the procurement of 2,400 bottles of Dectomax (Doramectin) 500mL Injectable Solution. This firm-fixed-price acquisition is a total small business set-aside under NAICS code 325414 and is intended to support the USDA Cattle Fever Tick Eradication Program in Texas. The required items must be new and the exact brand name specified from Zoetis Inc., as alternate or substitute products are deemed technically unacceptable. All deliverables must be shipped F.O.B. destination to Laredo, Texas, within 30 days of the contract award. Award will be made based on best value, specifically to the lowest priced, technically acceptable offer with an acceptable or neutral past performance rating. To be considered technically acceptable, offerors must provide sufficient documentation, such as manufacturer quotes or datasheets, to verify the product and ensure a clear, auditable paper trail of traceability back to the original equipment manufacturer. Additionally, contractors must furnish a Certificate of Conformance per FAR 52.246-15. Quotations must remain firm for 90 calendar days, and the deadline for submission is October 30, 2026.

POSTED

DEADLINE

Supplier of Pressure Sensitive Adhesive Tape (NSN 7510-01-358-8770)This subcontract involves the supply of Type I Code M pressure sensitive adhesive tape to prime contractors supporting Department of Defense DLA supply contracts. The material must strictly adhere to NSN 7510-01-358-8770 and RA001 technical specifications. The scope of work requires the delivery of eight rolls of mercury-free tape, each maintaining a minimum shelf life of 24 months. Compliance with federal standards is mandatory, including packaging per MIL-STD-2073-1E, marking per MIL-STD-129, and hazardous material labeling according to the Hazard Communication Standard. Deliveries are to be made FOB Origin to DLA Distribution San Joaquin in Tracy, California. The opportunity is categorized under NAICS code 325414.

CONSTRUCTION & EQUIPMENT T & IFO EQ

POSTED

DEADLINE

Supply of Defibrinated Rabbit BloodThis subcontract involves the supply of defibrinated rabbit blood to prime contractors supporting projects for the Defense Health Agency within the Department of Defense. The scope of work includes the collection of rabbit blood, the defibrination process to meet specific requirements, and the bottling of the product into 50ml units. To ensure quality and traceability, the provider must generate lot numbers and product data sheets for every unit produced. The execution of this contract requires the use of biological processing equipment and laboratory-grade bottling facilities. The total deliverable consists of 48 units of defibrinated rabbit blood per period of performance, with the place of performance located in Silver Spring, Maryland. This opportunity falls under NAICS code 325414 and is associated with a response deadline of October 23, 2026.

Defense Health Agency (dha)

POSTED

DEADLINE

PANDHA-26-P-0000 046638 Defibrinated Rabbit Blood

Solicitation # PANDHA-26-P-0000_046638

The Defense Health Agency Contracting Activity, acting on behalf of the Walter Reed Army Institute of Research, intends to award a sole source contract to Lampire Biological Labs, Inc. under FAR 6.302 for the procurement of defibrinated rabbit blood. The requirement is categorized under NAICS code 325414 for Biological Product Manufacturing. The contract structure consists of a base year followed by four one-year option periods, with a delivery requirement of 48 units per period of performance, where each unit is defined as one 50ml bottle. The contractor must ensure each unit is provided with a lot number and an associated product data sheet. Strict packaging and shipping standards are required to prevent leaks, spillage, and damage, while maintaining a temperature range of 2 to 8 degrees Celsius upon arrival at the destination in Silver Spring, Maryland. This procurement is being handled as a presolicitation notice of intent to sole source, with a response deadline for capability statements set for October 23, 2026.

Defense Health Agency (dha)

POSTED

DEADLINE

VAC to Finished Vaccine ConversionThis subcontract involves the conversion of Government-owned Vaccine Antigen Concentrate into final-use Foot and Mouth Disease vaccine doses for prime contractors supporting USDA APHIS projects. The scope of work includes formulating the concentrate into a usable vaccine, performing filling and packaging within cleanroom facilities, and conducting essential final potency and efficacy testing. The project is managed under the Department of Agriculture and will be performed in Ames, Iowa. To be eligible, the contractor must hold a USDA Veterinary Biological Product License. The solicitation was posted on October 1, 2026, with a response deadline of November 10, 2026, falling under NAICS code 325414.

POSTED

DEADLINE

FMD Vaccine Antigen Concentrate (VAC) ProductionThis subcontract for the Department of Agriculture involves the production of Foot and Mouth Disease Vaccine Antigen Concentrates for prime contractors on USDA APHIS projects. The scope of work includes the purification and concentration of VAC serials, which are produced by engineering Master Seed Viruses or utilizing field strains in accordance with 9 CFR Parts 113 and 114. To qualify, the provider must possess a USDA Veterinary Biological Product License and provide propagation cell line data approved by the Center for Veterinary Biologics. The final deliverables are purified and concentrated FMD VAC serials, with performance taking place in Ames, Iowa. The response deadline for this opportunity is November 10, 2026.

POSTED

DEADLINE

Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC)

Solicitation # 12639527R0001

Solicitation 12639527R0001 is a request for proposals issued by the USDA Animal and Plant Health Inspection Service (APHIS) for an Indefinite Delivery Indefinite Quantity (IDIQ) contract. The requirement covers the purchase, storage, and production of Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC), the conversion of Government-owned VAC into usable finished vaccines, and the direct purchase of finished vaccines. The contract has a ceiling price of 800 million dollars and a long-term performance horizon, featuring five one-year ordering periods starting approximately December 1, 2026, with conversion and delivery of finished vaccines extending through November 30, 2044. The scope of work requires the contractor to produce VAC capable of yielding at least 1.0 million doses and maintain these materials on their premises under strict quality control and temperature standards. Because live FMDV is a Tier 1 Select Agent, the contractor must hold a select agent authorization issued by CDC/APHIS. Finished vaccines must be packaged to maintain temperatures between 2 to 8 degrees Celsius for 24 hours and include electronic temperature monitors. Award will be based on the most advantageous offer considering technical capability, past performance from the last five years, and fair and reasonable pricing. Proposals must be submitted electronically to Stephen Tees by November 10, 2026, at 1700 CT, organized into four separate volumes.

POSTED

DEADLINE

Antithrombin III Procurement

Solicitation # CBP-CON-00260

The National Blood Authority is seeking tenders for the procurement of an Antithrombin III product under solicitation number CBP-CON-00260. While the agency currently maintains supply arrangements for Thrombotrol through the National Fractionation Agreement for Australia, this request for tender opens the process for the provision of these essential medical supplies. Interested parties must submit their responses by the deadline of November 20, 2026. All inquiries and submissions should be directed to the CBP Procurement Team via the provided contact email. Further detailed specifications and requirements are contained within the official request for tender documentation.

National Blood Authority

POSTED

DEADLINE

Biomedical Research and TestingThis subcontract for Biomedical Research and Testing is issued by the Defense Advanced Research Projects Agency under the U.S. Department of Defense. The project focuses on conducting human or animal use research for prime contractors involved in SBIR/STTR TRIAGE-X projects, requiring the use of IRB/IACUC certified facilities for bio-medical testing and clinical trial management. The primary objective is the delivery of comprehensive clinical trial data and bio-research findings. The opportunity is designated as a Total Small Business Set-Aside under the SBIR/STTR mandate for companies with fewer than 500 employees, falling under NAICS code 325414. Interested parties must submit their responses by October 21, 2026, following the posting date of September 23, 2026.

Defense Advanced Research Projects Agency

POSTED

DEADLINE

Proteomics and Protein Expression AnalysisThe Proteomics and Protein Expression Analysis subcontract supports National Institutes of Health projects focused on identifying biomarkers related to substance exposure and brain development. The selected provider will perform protein identification and quantification for prime contractors using a variety of high-sensitivity methods, including mass spectrometry, ELISA, Western blotting, and protein-protein interaction assays via LC-MS/MS. To ensure the integrity of the results, the performing laboratory must adhere to ISO/IEC 17025 quality standards. The primary deliverables for this engagement consist of detailed quantitative biomarker reports and comprehensive protein expression profiles. This effort falls under NAICS code 325414 and is managed through the Department of Health and Human Services.

National Institutes Of Health

POSTED

DEADLINE

Medical Diagnostic Test Kit SupplyThe Defense Logistics Agency under the Department of Defense has issued a subcontract for the supply of 100 E. coli detection test kits. These diagnostic kits must strictly adhere to FDA regulations, specific shelf-life requirements, and Department of Defense medical packaging standards to ensure quality and viability. Classified under NAICS code 325414, this procurement focuses on the delivery of specialized medical diagnostic tools. The contract was posted on August 11, 2026, and is managed through the DLA's acquisition systems to support military medical readiness.

Defense Logistics Agency

POSTED

DEADLINE

Medical Supply Procurement – Petrolatum GauzeThis subcontract with the Defense Logistics Agency under the Department of Defense involves the manufacture or supply of 27 units of petrolatum gauze, identified by NSN 6510-01-112-6414. The procurement falls under NAICS code 325414 and requires all units to meet strict military medical standards. Key delivery requirements include a minimum shelf life of 36 months, with a mandate that the time elapsed from manufacture to delivery does not exceed five months. The contract was posted on August 10, 2026.

Defense Logistics Agency

POSTED

2 months ago

DEADLINE

N/A

AI Contract Overview

The contract involves transcriptomics sequencing and analysis of liver spheroids to assess gene expression related to liver toxicity caused by antisense oligonucleotides (ASOs). The primary objective is to develop a predictive model for evaluating the safety and acute toxicity of candidate ASO therapies, utilizing data from human, rat, and mouse models. This effort aims to generate proof-of-concept data demonstrating the effectiveness of a 3D liver microtissue platform in predicting hepatotoxicity, which could lead to a more efficient, cost-effective, and high-throughput screening method for assessing potential liver toxicity of ASOs before clinical development. The project combines transcriptomics data with existing cell-based assays to improve the accuracy of safety predictions for future therapeutic candidates. The contract is issued by the National Institutes of Health, specifically through the National Center for Advancing Translational Sciences (NCATS), under the Department of Health and Human Services. It is posted with a response deadline of November 22, 2024, and is located in Rockville, Maryland, with work to be performed in Bethesda, Maryland. The initiative emphasizes advancing translational science by leveraging innovative microtissue platforms and gene expression analysis to enhance the safety profiling of novel therapeutics, ultimately aiming to streamline the pathway from preclinical testing to clinical application. The point of contact for this contract is Chandani Hangilipola, reachable via email and phone for further inquiries.

General Info

Contract for transcriptomics services to evaluate liver toxicity of antisense oligonucleotides in various models.

Agency

Department Of Health And Human Services → National Institutes Of Health Nida

NAICS

325414 - Biological Product (except Diagnostic) Manufacturing

Place of Performance

Rockville, MD, 20850, USA

Set-Aside

NONE

Documents

75N95025Q00040 Transcriptomics Sequencing and Analysis in Liver Spheroids

7 pages · rfq

High

FAR 52.204-24 Telecommunications and Video Surveillance Representation

3 pages · provision

High

FAR 52.212-4 Addendum (Nov 2021)

4 pages · amendment

High

Q3240134 Statement of Work - Transcriptomics Sequencing and Analysis

4 pages · sow

High

FAR 52.204-26 Covered Telecommunications Equipment or Services Representation (Oct 2020)

1 page · representation

Low

FAR 52.212-5 Contract Terms and Conditions (Nov 2024)

7 pages · contract-terms

Low

Invoice and Payment Provisions (IPP Updated 04/21/2022)

other

Low

NIH Invoicing Instructions Without IPP

other

Low

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

PhaseClosed

PostedNov 15

Combined Synopsis

Response DeadlineNov 22

Deadline has passed

Submission Closed

11/22/2024, 08:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → National Institutes Of Health Nida

Contacts1 person available

OfficeBethesda, MD, 20892, USA

Organization / AgencyDepartment Of Health And Human Services → National Institutes Of Health Nida

Office AddressBethesda, MD, 20892, USA

Contacts

Chandani Hangilipola

contact@example.gov

+1 (555) 000-0000

Full Description

The National Center for Advancing Translational Sciences (NCATS) requires transcriptomics sequencing and analysis in liver spheroids. This requisition is requesting a contract to evaluate the RNA expression in liver toxicity associated with the systemic administration of antisense oligonucleotides (ASOs) in previously tested human, rat and mouse animal models. The project's phase one goal is to develop a predictive model of candidate ASO therapies' safety and acute toxicity. NCATS is seeking technical support to evaluate the safety and acute liver toxicity of candidate ASOs by checking the gene expression. The results from these studies, in conjunction with existing cell-based assays, will help better predict the safety of future candidate ASOs intended for clinical use. The objective of this contract is to generate proof-of-concept data for evaluating the ability of the 3D liver microtissue platform to predict the hepatoxicity of individual ASOs. If successful, this will represent a new means to screen ASOs for this type of toxicity that is cheaper, faster, and has high throughput. NCATS is seeking technical support to evaluate the safety and acute liver toxicity of candidate ASOs by checking the gene expression. The results from these studies, in conjunction with existing cell-based assays, will help better predict the safety of future candidate ASOs intended for clinical use.